HomeMarket NewsMicro Cap StocksSeelos Therapeutics' Aggressive Alzheimer's Hopeful Candidate Shows Encouraging Preclinical Activity

Seelos Therapeutics' Aggressive Alzheimer's Hopeful Candidate Shows Encouraging Preclinical Activity

Actionable Trade Ideas

always free


Seelos Therapeutics Inc (NASDAQ: SEEL) has released preclinical data from a study evaluating SLS-005, its investigational drug for Alzheimer’s disease, in an aggressive non-human primate model. The study utilized tau overexpression in older non-human primates through bilateral AAV-induced tauopathy.

During the study, the non-human primates were administered either weekly doses of SLS-005, a single dose of SLS-009, or a control treatment. The preliminary analysis showed that the non-human primates treated with SLS-005 experienced a 46% reduction in tau protein and an 18% reduction in neurofilament light chain (NfL), a protein biomarker.

NfL is a non-specific biomarker for several neurodegenerative conditions, including Alzheimer’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).

In addition to the preclinical study, Seelos Therapeutics also expects to release top-line data from its Phase 2/3 trial of SLS-005 in ALS in the fourth quarter of 2023. The trial is being conducted as part of the HEALEY ALS Platform Trial led by Harvard Medical School at Massachusetts General Hospital.

In previous animal models, SLS-005 has shown promising results in reducing the aggregation of misfolded proteins and accumulation of pathologic material associated with various diseases.

It’s worth noting that Seelos Therapeutics recently announced that Part 2 of its Phase 2 study of SLS-002 for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder did not meet the pre-defined primary endpoint.

As of the latest update, SEEL shares are up 13.50% at $0.20 on Wednesday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.